GNT Pharma   Report issue

For profit Phase 3
Founded: Yongin United States (1998)

Organization Overview

First Clinical Trial
2016
NCT02831088
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

GNT Pharma

Active Ingredients

Drugs in Phase 3 Trials (1)

Nelonemdaz (3 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Cerebral Infarction (Phase 2)

Heart Arrest (Phase 2)

Ischemia (Phase 2)

Out-of-Hospital Cardiac Arrest (Phase 2)

Stroke (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 3
  • # of Trial APIs: 1